Abstract:1038 Background: The monitoring of circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) in patients with MBC predicts treatment resistance and prognosis. We previously reported that ESR1 alterations in ctDNA were associated with tumor tissue characteristics and CTCs which may predict metastasis and worse prognosis in MBC (2019 ASCO#1036, 2022 ASCO#1057). Furthermore, ctDNA can be used to evaluate tumor heterogeneity in MBC (2020 ASCO #1028). Here, we report a multi-factor analysis in ctDNA and CTC which may help to elucidate disease prognosis in MBC. Methods: This study included 391 MBC patients who received systemic treatment before 2022 under an IRB-approved clinical trial at NU Lurie Cancer Center. Whole blood samples (7.5ml/each) were collected from all patients at three time points including before treatment, three months, and six months after treatment for CTC enumeration using the CELLTRACKS system (Menarini). The corresponding ctDNA was analyzed by Guardant360 NGS evaluating 74-gene mutations. The maximum follow-up period was 380 months from first diagnosis. Causal Inference with Ensembel Learning was used for statistical analyses. Results: Of the 391 patients ctDNA analysis, TP53 mutations were found in 160 patients (TP53 Mut , 40.92%), CDH1 mutations were found in 21 patients (CDH1 Mut , 5.37%), Myc mutations were found in 53 patients (Myc Mut , 13.55%), and BRAF mutations were found in 35 patients (BRAF Mut , 8.95%) inclusive of all timepoints. The corresponding ctDNA mutations were not detected in 231 patients for TP53 (TP53 WT , 59.08%), in 370 patients for CDH1 (CDH1 WT , 94.63%), in 338 patients for Myc (Myc WT , 86.45%), or in 356 patients for BRAF (BRAF WT , 91.05%). There was shorter median overall survival (mOS) in the ctDNA mutated groups compared to the non-mutated groups: 88 months TP53 Mut vs 184 months TP53 WT , HR 1.91, P = 0.0002; 133 months CDH1 WT vs 81 months CDH1 Mut , HR 2.03, P = 0.02; 76 months Myc Mut vs 179 months Myc WT , HR 3.24, P < 0.0001, and 77 months BRAF Mut vs 146 months BRAF WT HR 2.45, P = 0.007. Furthermore, ≥5 CTCs were found in 32.42% patients. These patient had a shorter mOS compared to patients had no CTC detected at any time point (70.1 months vs 131 months; P < 0.001; HR 2.97). CTC-clusters were 50 times more likely to predict metastasis than single CTCs. We also found that greater than 5 CTC-clusters, clusters with 1-5, and no CTC-clusters were found in 12.55%, 11.25%, and 76.19% patients, respectively. Larger CTC-clusters had shorter mOS at 63 months, 121 months, and 163 months, respectively (P < 0.0001). Conclusions: In this study, we identified multiple liquid biopsy factors including ctDNA and CTC-clusters at various time points, and found that these are associated with prognosis. The synergy of multiple ctDNA mutations and CTC-clusters during treatment may expand the predictive role of liquid biopsy for the monitoring of disease progression in patients MBC.

Quantified CIN Score From Cell-free DNA as a Novel Noninvasive Predictor of Survival in Patients With Spinal Metastasis

HER2 Copy Number Quantification in Primary Tumor and Cell-Free DNA Provides Additional Prognostic Information in HER2 Positive Early Breast Cancer

Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Association Between Plasma Somatic Copy Number Variations and Response to Immunotherapy in Patients with Programmed Death-Ligand 1-Negative Non-Small Cell Lung Cancer

Development of a Plasma Cell-Free DNA Chromosome Instabilities Assay for Early Cancer Detection and Treatment Response Monitoring of Multiple Tumor Types.

Estimation of the Survival of Patients with Lung Squamous Cell Carcinoma Using Genomic Copy Number Aberrations

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Technical And Clinical Validation Of Somatic Cnv Detection From Circulating Tumor Dna.

The emergence of new prognostic scores in lung cancer patients with spinal metastasis: A 12-year single-center retrospective study

Multiple‐level copy number variations in cell‐free DNA for prognostic prediction of HCC with radical treatments

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features

Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study

The chromosomal instability 25 gene signature is identified in clear cell renal cell carcinoma and serves as a predictor for survival and Sunitinib response

Development and Validation of a Novel Survival Prediction Model in Patients with Spinal Metastasis from Non-small Cell Lung Cancer.

Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis

Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).

The value of chromosome instability detected by low−pass whole−genome sequencing in preoperative prediction of sentinel lymph node metastasis in breast cancer

Bone metastasis prediction in non-small-cell lung cancer: primary CT-based radiomics signature and clinical feature

Role of Circulating Free DNA in Evaluating Clinical Tumor Burden and Predicting Survival in Chinese Metastatic Colorectal Cancer Patients

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers